Premium
Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation
Author(s) -
Tanaka Tomoyuki,
Rabbitts Terence H.
Publication year - 2003
Publication title -
the embo journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.484
H-Index - 392
eISSN - 1460-2075
pISSN - 0261-4189
DOI - 10.1093/emboj/cdg106
Subject(s) - biology , intracellular , cytoplasm , immunoprecipitation , microbiology and biotechnology , fusion protein , mutagenesis , transformation (genetics) , antibody , computational biology , biochemistry , recombinant dna , mutation , genetics , gene
We have applied in vivo intracellular antibody capture (IAC) technology to isolate human intrabodies which bind to the oncogenic RAS protein. IAC facilitates the capture of antibody fragments, in this case single‐chain Fvs (scFvs), which tolerate reducing environments, such as the cytoplasm of cancer cells. Three anti‐RAS scFvs with different affinity, solubility and intracellular binding activity were characterized. The anti‐RAS scFvs with highest affinity were expressed relatively poorly in mammalian cells, and greater soluble expression was achieved by mutating the antibody framework to canonical consensus scaffolds, previously derived from IAC, without losing antigen specificity. Mutagenesis experiments showed that the consensus scaffolds are functional as intrabody fragments without an intra‐domain disulfide bond. Furthermore, we could convert an intrabody which does not bind RAS in mammalian cells into a high‐affinity reagent capable of inhibiting RAS‐mediated NIH 3T3 transformation by exchanging VH and VL complementarity‐determining regions onto its consensus scaffold. These data show that the consensus scaffold is a robust framework by which to improve intrabody function.